LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline.
Reeves, Emer P
Chotirmall, Sanjay H
Greene, Catherine M
O'Neill, Shane J
McElvaney, Noel G
AffiliationDepartment of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland. email@example.com
Antimicrobial Cationic Peptides
Nebulizers and Vaporizers
Protein Processing, Post-Translational
Saline Solution, Hypertonic
MetadataShow full item record
CitationLL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. 2009, 183 (1):543-51 J. Immunol.
JournalJournal of immunology (Baltimore, Md. : 1950)
AbstractThere is an abundance of antimicrobial peptides in cystic fibrosis (CF) lungs. Despite this, individuals with CF are susceptible to microbial colonization and infection. In this study, we investigated the antimicrobial response within the CF lung, focusing on the human cathelicidin LL-37. We demonstrate the presence of the LL-37 precursor, human cathelicidin precursor protein designated 18-kDa cationic antimicrobial protein, in the CF lung along with evidence that it is processed to active LL-37 by proteinase-3. We demonstrate that despite supranormal levels of LL-37, the lung fluid from CF patients exhibits no demonstrable antimicrobial activity. Furthermore Pseudomonas killing by physiological concentrations of exogenous LL-37 is inhibited by CF bronchoalveolar lavage (BAL) fluid due to proteolytic degradation of LL-37 by neutrophil elastase and cathepsin D. The endogenous LL-37 in CF BAL fluid is protected from this proteolysis by interactions with glycosaminoglycans, but while this protects LL-37 from proteolysis it results in inactivation of LL-37 antimicrobial activity. By digesting glycosaminoglycans in CF BAL fluid, endogenous LL-37 is liberated and the antimicrobial properties of CF BAL fluid restored. High sodium concentrations also liberate LL-37 in CF BAL fluid in vitro. This is also seen in vivo in CF sputum where LL-37 is complexed to glycosaminoglycans but is liberated following nebulized hypertonic saline resulting in increased antimicrobial effect. These data suggest glycosaminoglycan-LL-37 complexes to be potential therapeutic targets. Factors that disrupt glycosaminoglycan-LL-37 aggregates promote the antimicrobial effects of LL-37 with the caveat that concomitant administration of antiproteases may be needed to protect the now liberated LL-37 from proteolytic cleavage.
- Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis.
- Authors: Reeves EP, Williamson M, O'Neill SJ, Greally P, McElvaney NG
- Issue date: 2011 Jun 1
- Beta-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis.
- Authors: Chen CI, Schaller-Bals S, Paul KP, Wahn U, Bals R
- Issue date: 2004 Mar
- Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum.
- Authors: Bucki R, Byfield FJ, Janmey PA
- Issue date: 2007 Apr
- IL-8 dictates glycosaminoglycan binding and stability of IL-18 in cystic fibrosis.
- Authors: Reeves EP, Williamson M, Byrne B, Bergin DA, Smith SG, Greally P, O'Kennedy R, O'Neill SJ, McElvaney NG
- Issue date: 2010 Feb 1
- Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo.
- Authors: Scott A, Weldon S, Buchanan PJ, Schock B, Ernst RK, McAuley DF, Tunney MM, Irwin CR, Elborn JS, Taggart CC
- Issue date: 2011